Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.
Immune-checkpoint inhibitor
PD-L1
PD1
immune-related adverse events
lung cancer
Journal
Oncology reviews
ISSN: 1970-5565
Titre abrégé: Oncol Rev
Pays: Switzerland
ID NLM: 101519906
Informations de publication
Date de publication:
06 Jul 2020
06 Jul 2020
Historique:
received:
24
03
2020
accepted:
14
04
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
epublish
Résumé
Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlighting possible inter- and intra-class dissimilarities, anti-PD1 agents showed a higher response rate and a better outcome when combined with chemotherapy for the first-line treatment of patients with squamous and PD-L1 low advanced NSCLC, as compared to anti-PD-L1 agents. Conversely, anti-PD-L1 agents were responsible for less severe adverse events (AEs), particularly, immunerelated AEs. These differences could be explained by their different specific properties. Considering possible differences between anti-PD1 and anti-PD-L1 agents could be clinically relevant for treatment tailoring and inspiring new investigational approaches.
Identifiants
pubmed: 32782728
doi: 10.4081/oncol.2020.490
pmc: PMC7385529
doi:
Types de publication
Journal Article
Langues
eng
Pagination
490Informations de copyright
©Copyright: the Author(s).
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Crit Rev Oncol Hematol. 2018 Sep;129:27-39
pubmed: 30097235
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Cancer Biomark. 2011-2012;10(2):79-89
pubmed: 22430135
J Immunother Cancer. 2018 Dec 3;6(1):135
pubmed: 30509312
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533
pubmed: 29951303
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Front Oncol. 2019 Apr 16;9:264
pubmed: 31058078
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Front Immunol. 2019 Feb 26;10:292
pubmed: 30863404
J Thorac Oncol. 2020 Feb;15(2):288-293
pubmed: 31622733
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Oncotarget. 2014 Dec 30;5(24):12472-508
pubmed: 25537519
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270
pubmed: 29127120
Oncotarget. 2015 Jun 30;6(18):15716-7
pubmed: 26158547
Crit Rev Oncol Hematol. 2019 Dec;144:102812
pubmed: 31698313
Lancet Respir Med. 2019 Apr;7(4):347-357
pubmed: 30876831
J Thorac Oncol. 2015 Dec;10(12):1685-93
pubmed: 26484629
Clin Lung Cancer. 2014 Nov;15(6):411-417.e4
pubmed: 25242668
Ann Oncol. 2019 Jun 1;30(6):884-896
pubmed: 30912805
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Clin Lung Cancer. 2018 Jan;19(1):93-104
pubmed: 28645631
Cancer. 2018 Jan 15;124(2):271-277
pubmed: 28960263
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Mod Pathol. 2016 Oct;29(10):1165-72
pubmed: 27389313
Cancer Discov. 2014 Oct;4(10):1140-53
pubmed: 25096233
Cancer. 2018 May 1;124(9):2010-2017
pubmed: 29469949
Eur Urol. 2015 Dec;68(6):959-67
pubmed: 26238431
JAMA Oncol. 2019 Jul 1;5(7):934-935
pubmed: 31145420
Sci Rep. 2019 Aug 7;9(1):11472
pubmed: 31391510
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
JAMA Oncol. 2019 Jul 1;5(7):1008-1019
pubmed: 31021376
Eur J Cancer. 2019 Jan;107:124-132
pubmed: 30562710
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Ther Adv Med Oncol. 2018 Oct 11;10:1758835918804151
pubmed: 30344651
Clin Lung Cancer. 2013 Jul;14(4):390-8
pubmed: 23313173
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
J Exp Clin Cancer Res. 2011 May 06;30:50
pubmed: 21548925